MedTrace Logo

Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer

NCT05379907 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-09-06

No results posted yet for this study

Summary

The purpose of this study is to collect information about treatment recommendations based on ctDNA testing and whether treatment changes based on ctDNA information result in better outcomes for patients with pancreatic cancer.

Conditions

Interventions

OTHER

SIGNATERA™ ctDNA testing

Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.

Sponsors & Collaborators

  • Natera, Inc.

    collaborator INDUSTRY

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Raymond Wadlow, MD · Inova Schar Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-23
Primary Completion
2023-08-23
Completion
2023-08-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05379907 on ClinicalTrials.gov